Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1992 3
1993 1
1994 2
1995 4
1996 1
1997 1
1998 1
1999 1
2000 1
2001 3
2002 2
2003 4
2004 3
2005 6
2006 3
2007 3
2009 2
2010 3
2011 3
2012 2
2013 3
2014 1
2015 4
2016 3
2017 1
2018 2
2019 3
2020 6
2021 4
2022 3
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.
Reckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B, Al Baghdadi T, Hines S, Everhart L, Highleyman L, Papadimitrakopoulou V, Neal JW, Waqar SN, Patel JD, Gray JE, Gandara DR, Kelly K, Herbst RS. Reckamp KL, et al. Among authors: dragnev kh. J Clin Oncol. 2022 Jul 20;40(21):2295-2306. doi: 10.1200/JCO.22.00912. Epub 2022 Jun 3. J Clin Oncol. 2022. PMID: 35658002 Free PMC article. Clinical Trial.
Pragmaticism in Cancer Clinical Trials.
Sankar K, Redman MW, Dragnev KH, Henick BS, Iams WT, Blanke CD, Herbst RS, Gray JE, Reckamp KL. Sankar K, et al. Among authors: dragnev kh. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e100040. doi: 10.1200/EDBK_100040. Am Soc Clin Oncol Educ Book. 2024. PMID: 38771997 Free article. Review.
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC, Zhu J, Desai K, Kinsey E, Kao C, Lee YH, Pabla S, Labriola MK, Tran J, Dragnev KH, Tafe LJ, Dayyani F, Gupta RT, McCall S, George DJ, Glenn ST, Nesline MK, George S, Zibelman M, Morrison C, Ornstein MC, Zhang T. Brown LC, et al. Among authors: dragnev kh. J Immunother Cancer. 2022 Oct;10(10):e005249. doi: 10.1136/jitc-2022-005249. J Immunother Cancer. 2022. PMID: 36252996 Free PMC article.
Nonclassical retinoids and lung carcinogenesis.
Dragnev KH, Petty WJ, Ma Y, Rigas JR, Dmitrovsky E. Dragnev KH, et al. Clin Lung Cancer. 2005 Jan;6(4):237-44. doi: 10.3816/CLC.2005.n.003. Clin Lung Cancer. 2005. PMID: 15694016 Review.
The retinoic acid paradox in cancer chemoprevention.
Freemantle SJ, Dragnev KH, Dmitrovsky E. Freemantle SJ, et al. Among authors: dragnev kh. J Natl Cancer Inst. 2006 Apr 5;98(7):426-7. doi: 10.1093/jnci/djj116. J Natl Cancer Inst. 2006. PMID: 16595769 No abstract available.
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).
Vaidya R, Unger JM, Qian L, Minichiello K, Herbst RS, Gandara DR, Neal JW, Leal TA, Patel JD, Dragnev KH, Waqar SN, Edelman MJ, Sigal EV, Adam SJ, Malik S, Blanke CD, LeBlanc ML, Kelly K, Gray JE, Redman MW. Vaidya R, et al. Among authors: dragnev kh. JCO Precis Oncol. 2023 Sep;7:e2300218. doi: 10.1200/PO.23.00218. JCO Precis Oncol. 2023. PMID: 37677122
Uncovering novel targets for cancer chemoprevention.
Dragnev KH, Feng Q, Ma Y, Shah SJ, Black C, Memoli V, Nugent W, Rigas JR, Kitareewan S, Freemantle S, Dmitrovsky E. Dragnev KH, et al. Recent Results Cancer Res. 2007;174:235-43. doi: 10.1007/978-3-540-37696-5_21. Recent Results Cancer Res. 2007. PMID: 17302201 Review.
Docetaxel in the treatment of esophageal cancer.
Rigas JR, Dragnev KH, Bubis JA. Rigas JR, et al. Among authors: dragnev kh. Semin Oncol. 2005 Apr;32(2 Suppl 4):S39-51. doi: 10.1053/j.seminoncol.2005.04.005. Semin Oncol. 2005. PMID: 16015553 Review.
87 results